Foley Hoag Represents Glympse Bio in $46.7M Series B Financing

July 23, 2020

Foley Hoag represented Glympse Bio, a biotechnology company advancing the way diseases are understood, tracked, and treated, in a $46.7 million Series B financing. The financing round was led by Section 32, with participation from new investors Temasek, DNS Capital, New Leaf Venture Partners, Waterman Ventures, and Catalio Capital Management, and existing investors, LS Polaris Innovation Fund, ARCH Venture Partners, CRV, GreatPoint Ventures, Gilead Sciences, and others. The proceeds from the financing will support continued development of Glympse’s novel biosensor platform in Non-Alcoholic Steatohepatitis (NASH), as well as support further development of the company’s oncology program and initiate development of its infectious disease program.

Founded in 2015 and headquartered in Cambridge, MA, Glympse is an MIT spin-out focused on better understanding diseases to transform disease detection and predict treatment response. The company is transforming the measurement of disease progression in vivo using bioengineered, tunable sensors that are designed for each protease-mediated disease. Foley Hoag has represented Glympse since it was first incorporated.

Foley Hoag lawyers Jeff Quillen, Nicola Lemay, Brendan Burke and Anna Snook represented Glympse in the transaction. 

About Foley Hoag LLP

Foley Hoag provides innovative, strategic legal services to public, private and government clients across the globe. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse backgrounds, perspectives and experiences of our lawyers and staff contribute to the exceptional senior level service we deliver to clients ranging from startups to multinational companies to sovereign states. For more information, visit www.foleyhoag.com or follow @FoleyHoag on Twitter.